Norway

Reimbursed Care Access

Norway maintains a broadly prohibitive criminal/drug-scheduling regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, 5‑MeO‑DMT, 2C‑series, ibogaine, ayahuasca), while ketamine-based treatments have an evolving medical pathway: esketamine (Spravato) has not been adopted into public reimbursement, whereas off‑label intravenous racemic ketamine has been authorized for use within specialist services and publicly reimbursed for treatment‑resistant depression under strict conditions as of August 25, 2025. Access to other psychedelics is effectively limited to approved clinical research or is entirely prohibited outside of statutory exceptions.